Blog
    Regulatory UpdateFor PhysiciansApril 23, 2026

    FDA peptide compounding status and safety signals

    Review the regulatory status of BPC-157, TB-500, and GLP-1 agonists. Learn about 503A compounding restrictions and emerging safety signals from FAERS data.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Clinical Question

    What is the current regulatory status of commonly used peptides, and what safety signals have emerged from clinical trials and post-marketing surveillance?

    Evidence Snapshot

    • Regulatory Monitoring: 10 peptides evaluated for FDA approval status, 503A/503B compounding eligibility, and warning letters.
    • Safety Signals: 10 distinct adverse event signals identified via FAERS for GLP-1 receptor agonists.
    • Clinical Outcomes: Data derived from Phase II and Phase III trials including STEP 1, SELECT, SURMOUNT-1, and SURMOUNT-5.
    • Regulatory Grade: 503A/503B Category 2 classifications denoting significant safety risks or lack of clinical-need exemptions.

    What the Research Shows

    FDA Regulatory Status and Warning Letters As of March 2026, several widely discussed peptides remain unapproved by the FDA and face significant compounding restrictions. BPC-157, TB-500, GHK-Cu, and Semax are classified under Category 2 for 503A compounding, which indicates significant safety risks or immunogenicity concerns, making them ineligible for routine compounding. Specifically, BPC-157 was classified as Category 2 in September 2023 due to a lack of safety data and immunogenicity risks.

    Several peptides that previously held nominations for compounding have seen those nominations withdrawn or removed as of September 2024. These include AOD-9604, CJC-1295, Selank, and Ipamorelin. The FDA cited safety issues such as increased heart rate for CJC-1295. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved and was removed from Category 2 pending advisory review in September 2024, although it remains a substance of concern under interim policy.

    Warning letters have been issued to entities such as Tailor Made Compounding (2020) and Predator Nutrition (October 2020) regarding several of these substances, including BPC-157, Thymosin Alpha-1, TB-500, and GHRP-2.

    Clinical Trial Efficacy and Safety Data Research into approved and investigational metabolic peptides demonstrates potent weight loss and cardiovascular outcomes. Phase III trials for Semaglutide (STEP 1) and Tirzepatide (SURMOUNT-1) reported weight loss of 14.9% and 22.5%, respectively. The SELECT trial for Semaglutide demonstrated a 20% reduction in Major Adverse Cardiovascular Events (MACE). In a direct comparison (SURMOUNT-5), Tirzepatide was found to be superior to Semaglutide for its studied indication.

    Investigational compounds show similar trajectories; Retatrutide (Phase II) reported 24.2% weight loss at a 12mg dose. Conversely, clinical data for Thymosin Alpha-1 in sepsis (Phase III TESTS trial) showed negative results with no reduction in mortality.

    Mechanism

    Based on provided clinical evidence and regulatory notes:

    • Metabolic Regulation: Semaglutide and Tirzepatide act as GLP-1 receptor agonists, with Tirzepatide showing superior efficacy in head-to-head obesity trials.
    • Growth Hormone Stimulation: CJC-1295 and Ipamorelin are associated with growth hormone pathways, with CJC-1295 notably impacting heart rate.
    • Immunogenicity: The FDA identifies immunogenicity—the ability of a substance to provoke an immune response—as a primary safety concern for BPC-157, TB-500, GHK-Cu, and GHRP-2.
    • Gastrointestinal Transit: GLP-1 agents like Semaglutide contribute to delayed gastric emptying, which influences both therapeutic effect and potential complications.

    Limitations of the Evidence

    Significant evidence gaps exist for many peptides currently in Category 2. The FDA notes a complete lack of human exposure data for TB-500. BPC-157 is limited by a lack of published safety data. While peptides like Selank and Semax are approved in Russia, they lack FDA approval or comprehensive US-based clinical trial data.

    For Semaglutide, several safety signals are characterized as "emerging" or "under evaluation." This includes NAION (96 cases through December 2024) and suicidal ideation, for which current data do not support a higher risk than background levels but still require monitoring.

    Clinical Takeaway

    Many peptides frequently utilized in clinical settings, such as BPC-157 and Thymosin Alpha-1, are not FDA-approved and are currently restricted from routine compounding due to safety signals or lack of clinical necessity data. While GLP-1 agonists show strong efficacy in Phase III trials, they are associated with dose-dependent gastrointestinal events and emerging signals including pulmonary aspiration and NAION. Physicians should prioritize substances with established FDA approval and monitor for evolving safety signals in post-marketing surveillance.

    Sources

    1. Regulatory Status Records: BPC-157 (0abdad3c), Thymosin Alpha-1 (68b0b103), TB-500 (c8181049), CJC-1295 (1a160b34), AOD-9604 (96fb1240).
    2. FAERS Safety Signals: Semaglutide signals (502f8ab5, d2135902, be753983, 60c7beaa).
    3. Clinical Trial Records: STEP 1 (NCT03548935), SELECT (NCT03574597), SURMOUNT-1 (NCT04184622), SURMOUNT-5 (NCT05024032), TESTS (NCT02867267).

    Referenced Peptides

    bpc 157semaglutidethymosin alpha 1tirzepatidecjc 1295

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.